Baxiva AG

About us

Baxiva is a biotechnology startup developing next-generation glycoconjugate vaccines to prevent infections caused by Gram-negative bacterial pathogens. Our lead vaccine candidate targets Escherichia coli, the leading cause of urinary tract infections worldwide, and a major contributor to antimicrobial resistance. Backed by cutting-edge science and operating in Schlieren and on ETH Zurich’s Hönggerberg campus, Baxiva offers a unique opportunity to contribute to high-impact science with real-world clinical potential. We are a small team of agile and highly motivated scientists. You will be working in a friendly and open environment where everyone contributes their own experience and expertise. We believe that science is most productive in an environment of open exchange, trust and collaboration. We are committed to fostering the personal growth of each team member.